Burlingame, CA


9:30am - 5:00pm

The advent of many creative and innovative therapeutic platforms such as antibody-drug conjugates (ADC), bispecific proteins as T cell engagers (BiTEs, DARTs, BisAbs, etc), scFv, CAR-T and many others have provided a plethora of new potential therapeutic options for patients. While these new innovative platforms may show great promise for patients they also present unique development challenges to the biopharm industry, especially in the areas of constructing and executing a preclinical safety program that will help to understand and mitigate the safety risks, determination of the starting dose in first-in-human trials of these very potent agents, understanding how target and disease burden play a role in patient selection and safety assessment and ultimately, how all of this is taken into account by Health Authorities around the world.

The objective of this symposium is to showcase the recent success and emerging trends of preclinical and early phase drug development efforts by leading experts from pharma, biotech and academia to encourage discussions and networking opportunities for our CABS members and other biopharma professionals in the Bay Area.

Lunch will be provided. Limited seats. RSVP is required. Please register as early as possible.


9:30AM - 10:00AM Registration and Check-in

10:00AM -10:10AM Welcome remarks and introduction of CABS (Yan Wang, Ph.D, CABS President)

10:10AM - 11:10AM Challenges and Approaches in the Early Development of Biologic Therapeutics

Speaker: Hugh M. Davis, Ph.D. Chief Business Officer (CBO), in charge of Business Development, Sales, Marketing and Strategic Partnerships for Frontage Laboratories, Inc.

11:10AM - 12:10PM Presentation Title: TBD

Speaker: Steven Chamow, Ph.D, Vice President of Development at Aridis Pharmaceuticals, Inc.

12:10PM - 1:00PM Lunch

1:00PM - 2:00PM Early Clinical Development in the US - Experiences with Chinese Pharmaceutical Companies

Speaker: Yuanchao (Derek) Zhang, Ph.D, President, Alavanda Regulatory & Drug Development Consulting, Inc.

2:00PM - 3:00PM Considerations for Early Stage Trials from a Clinical Pharmacology Perspective

Speaker: Mark T. Marino, MD, Chief Medical Officer at Imugene Ltd.

3:00PM - 3:15PM Coffee break

3:15PM - 4:15PM Panel discussion


Hugh M. Davis, Ph.D

Mark T. Marino, MD

Yuanchao (Derek) Zhang, Ph.D

Steven Chamow, Ph.D

4:15PM - 4:45 PM Networking

Click Here for More Information

Contact: Jin Zhang
Contact Email:

Event Address:

DoubleTree Hotel (835 Airport Blvd, Burlingame, CA 94010)